Compare · ACRV vs NVO
ACRV vs NVO
Side-by-side comparison of Acrivon Therapeutics Inc. (ACRV) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACRV and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 2974.7x ACRV ($74.9M).
- NVO has hit the wire 4 times in the past 4 weeks while ACRV has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 11 for ACRV).
- Company
- Acrivon Therapeutics Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $74.9M
- $222.81B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- News (4w)
- 0
- 4
- Recent ratings
- 11
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ACRV
- SEC Form 4 filed by Director Ra Capital Management, L.P.
- SEC Form 4 filed by Director Tomsicek Michael John
- SEC Form 4 filed by Director Shacham Sharon
- SEC Form 4 filed by Director Palani Santhosh
- SEC Form 4 filed by Director Magovcevic-Liebisch Ivana
- SEC Form 4 filed by Director Dirocco Derek
- SEC Form 4 filed by Director Baum Charles M
- Acrivon Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- President and CEO Blume-Jensen Peter covered exercise/tax liability with 13,729 shares (SEC Form 4) to satisfy tax liability
- SEC Form DEFA14A filed by Acrivon Therapeutics Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S